Cardio-oncology — cancer therapy-related cardiac dysfunction
Chemotherapy cardiotoxicity · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Anthracyclines, HER2-targeted agents, VEGF inhibitors and immune checkpoint inhibitors can impair cardiac function or cause myocarditis. Baseline risk stratification, surveillance imaging and biomarkers allow early detection and cardioprotective treatment while continuing cancer therapy where possible.
Red flags
- Chest pain, arrhythmia or conduction block during checkpoint-inhibitor therapy
- Rapidly falling LVEF on surveillance imaging
- New heart failure symptoms during chemotherapy
- Troponin rise with immunotherapy (myocarditis)
- Uncontrolled hypertension on VEGF inhibitors
Assessment
Differential diagnosis
- Anthracycline-induced cardiomyopathy
- HER2 (trastuzumab)-related dysfunction
- Checkpoint-inhibitor myocarditis
- VEGF inhibitor hypertension/dysfunction
- Pre-existing cardiomyopathy
- Sepsis or anaemia-related dysfunction
Investigations
- Baseline TTE with global longitudinal strain
- Baseline and serial troponin and natriuretic peptides
- 12-lead ECG
- Cardiac MRI if myocarditis suspected
- Repeat echo at intervals defined by drug and risk
- Monitor BP during VEGF inhibitor therapy
Management
- Risk-stratify before cancer therapy using baseline cardiac function and risk factors
- Record baseline LVEF, GLS and biomarkers
- Optimise cardiovascular risk factors and treat hypertension before/ during therapy
- Schedule surveillance echo per drug class and cumulative anthracycline dose
- Define cardiotoxicity by LVEF fall ≥10% to below normal, or GLS fall ≥15%
- Start ACEi/ARB and beta-blocker for asymptomatic decline or overt dysfunction
- Add an SGLT2 inhibitor and MRA for established HFrEF
- Hold cardiotoxic agent and discuss risk-benefit with oncology for significant decline
- For suspected checkpoint-inhibitor myocarditis, stop the drug and start high-dose steroids urgently
- Consider dexrazoxane or liposomal anthracycline in high-risk anthracycline exposure
- Coordinate decisions jointly between cardiology and oncology
- Arrange long-term survivorship cardiac follow-up
Drugs & doses
Ramipril 2.5-10 mg PO OD (or candesartan 8-32 mg OD)
Bisoprolol 2.5-10 mg PO OD (carvedilol an alternative)
Methylprednisolone 500-1000 mg IV daily for checkpoint-inhibitor myocarditis
Dexrazoxane IV (10:1 ratio to doxorubicin) as cardioprotection in high-risk anthracycline use
Empagliflozin 10 mg PO OD for established HFrEF
Eplerenone 25-50 mg PO OD for HFrEF with cardiotoxicity
Disposition
Joint cardio-oncology clinic. Admit for suspected checkpoint myocarditis or decompensated heart failure; coordinate ongoing cancer therapy with oncology.
Complications & pitfalls
- Irreversible heart failure
- Fulminant immune checkpoint myocarditis (high mortality)
- Arrhythmia and sudden death
- Treatment interruption compromising cancer control
- Accelerated atherosclerosis after radiotherapy
Exam pearls
- Checkpoint-inhibitor myocarditis is rare but can be rapidly fatal — treat early with steroids
- A fall in global longitudinal strain precedes a measurable LVEF drop
- Many anthracycline cardiomyopathies improve with prompt heart failure therapy
- Dexrazoxane protects against cumulative anthracycline toxicity in high-risk patients
- Radiotherapy accelerates coronary, valvular and pericardial disease years later
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.